The demand for medicinal products derived from plasmas are increasing on a global scale. In particular, the demand for intravenous immunoglobulin has continuously been increasing. The increase in the capacity of commercial plasma fractionators is prominent compared with that of non-profit plasma fractionators; thus, the percentage of plasmapheresis has increased with respect to that of plasma from whole blood. The inequality between the consumption of plasma-derived medicinal products and supply of raw plasma among developed countries and developing countries is due to the direct, proportional relationship between the consumption of plasma-derived medicinal products and the size of gross domestic products. Each country decides on its own system to achieve a stable supply of plasma-derived medicinal products. Although domestic production is an ideal option, many countries establish contracts with plasma fractionators. Owing to a great ripple effect, safety measures are increasingly applied, so detailed review should be conducted with consideration given to the cost-effectiveness and the situation unique to each country.